Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
PAVmed Inc. is a medical device company focused on developing innovative solutions for unmet medical needs, particularly in the areas of gastroenterology and surgical procedures. The company's flagship products include the CarpX device for carpal tunnel syndrome and the Lucid diagnostic platform for gastrointestinal applications, which are designed to improve patient outcomes and reduce healthcare costs.
PAVmed generates revenue primarily through the sale of its proprietary medical devices. The company leverages a direct sales force and partnerships with distributors to reach healthcare providers. Its competitive advantages include a focus on innovative, minimally invasive technologies that address significant clinical needs, potentially leading to better patient outcomes and cost savings for healthcare systems.
FDA approval timelines for new devices
Market adoption rates of existing products
Partnership agreements with larger medical device companies
Changes in reimbursement policies affecting device sales
Regulatory changes affecting medical device approvals and market access
Technological disruption from competitors introducing superior products
Intense competition from established medical device manufacturers
Potential for new entrants in the minimally invasive device market
Negative cash flow impacting liquidity and operational flexibility
Potential difficulties in raising capital for future growth initiatives
moderate - PAVmed's performance is somewhat linked to healthcare spending, which can be influenced by economic cycles.
Higher interest rates could increase financing costs for PAVmed, impacting its ability to fund R&D and operations, though the direct impact is limited as the company is not heavily reliant on debt.
minimal - PAVmed's debt levels are manageable, and it does not have significant reliance on credit markets.
growth - investors looking for high-risk, high-reward opportunities in innovative healthcare solutions.
high - the stock has exhibited significant price volatility, particularly given its recent performance.
